FGFR2 M538I

CI-VAR-00417092Explore in graph →CIViC 5579

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Hepatocellular Carcinoma1
FGFR2 M538I	Sorafenib	Predictive	C	Supports Sensitivity Response	1	submitted	EID13271 Among 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, one patient whose tumor harbored FGFR2 M538I achieved a partial response. The same tumor also harbored FGFR4 G665E, pr… (full text at CIViC) PMID 27384874 · Kaibori et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.